KEI and UACT comments on NIH license to GLG Pharma over a STAT3 Inhibitor “in all proliferative diseases.”
On June 7, 2019, KEI and UACT submitted comments to the Federal Register notice 84 FR 23798, on the “Prospective Grant of an Exclusive Patent License: The Development and Use of a Therapeutic STAT3 Inhibitor, GLG-302, in All Proliferative Diseases,… Continue Reading